ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
about
Trial watch - inhibiting PARP enzymes for anticancer therapyTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerTargeting the Checkpoint to Kill Cancer CellsSystems biology of cisplatin resistance: past, present and futureSynthetic lethality in lung cancer and translation to clinical therapiesEvaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer.Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cellsPotentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970Development of synthetic lethality anticancer therapeutics.ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.Deciphering the BRCA1 Tumor Suppressor Network.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.Replication stress and cancer: it takes two to tango.ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.Molecular Pathways: Targeting ATR in Cancer TherapyDNA replication stress and cancer: cause or cure?Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.Targeting the ATR-CHK1 Axis in Cancer TherapyATR inhibition rewires cellular signaling networks induced by replication stress.Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.Radiosensitization of human leukemic HL-60 cells by ATR kinase inhibitor (VE-821): phosphoproteomic analysis.Development of pharmacodynamic biomarkers for ATR inhibitors.Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer CellsATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine.Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair.
P2860
Q26745673-7FC2B50D-955F-49BD-BF07-DF675615CB17Q26745686-A7B970D8-FED6-462C-ADB8-B1B326771D21Q26776513-23C2958F-7CF4-4542-B7F6-CCF5AFF6A3EAQ26795781-E3448A7E-8E38-4972-A947-1FBC615D6807Q26863585-A6FD0560-1C48-492D-9FE2-6B5A2E12CA6AQ28072904-6D1885F1-9FF9-4D8C-958B-6615B55F19FBQ33925006-0CCF4D0E-651D-42AA-AB5B-15A6D6A168CCQ34221822-43CCB679-9FC5-4379-BB55-9F64A0282958Q34221860-CA188BEC-E102-4B94-87F2-9075361F542EQ34380368-AC79CB2C-6321-4A0F-9683-9B628897CA90Q34614944-95255565-EADD-48FB-911E-C69E593D30F1Q34982593-1314FD71-278E-42F5-9EDA-BBD4128C0ED9Q35232784-2EECA67A-A88B-404D-9763-4CA0336BEF24Q35246419-E9104137-7924-4CAF-A508-04A09B9439C8Q35627868-7E8831AC-E43F-4CFA-A182-5871C0FDAAF5Q35799909-16BEEB9C-DC47-4278-9F5B-371A1CC37C5DQ35859458-2FC38451-FB9D-482F-B6BE-DAFEB66DEE4EQ35895214-3B74C352-D456-4500-B355-A42C1C78E449Q36189324-E9EB1CA7-B848-4762-9CEA-3FCB81AFF2B1Q36855596-C5F85062-3FC9-4AFE-AAD2-B102869BDBE0Q36931593-F5305858-F537-4E60-9822-95309BF8AABDQ37508792-4370A24D-B933-403E-AB81-BE35A5D2BC1AQ37558633-711DD2A0-01E1-4286-8945-48A57DE40997Q37676283-DF50899B-16C6-4880-AA2A-260132F069A3Q37691597-33B91D8D-FCEC-40CE-AF80-F27192A9A5BEQ38142158-3F4F6F05-C0EE-49F3-B859-161887244E6BQ38585436-86004DF3-0397-4E39-80E5-FB7B1D41CBE1Q38652528-D0C750C0-8625-47B1-92D4-E8368F47DB15Q38739456-73D7C023-61E4-4F41-9A90-7CB741ABCDBDQ38805276-65F52F32-B4F3-4DA3-8821-2DC127F02A4FQ38817102-46F0EAC7-50DB-458F-8FA5-28771E289EA4Q38819342-70EA8A8D-6B96-4D6F-8B8E-F3FA7CAE97CAQ38856683-FF6351A3-D509-4902-B599-4A5F4F258BF4Q38977190-668EEC24-6E72-41BA-92A1-C00B990A948FQ41135683-1FCA810B-5CC5-4105-B309-DB16036F4EBAQ41470356-6C597BD8-9316-41AB-9BFA-A80689E23988Q42315217-BAD8022D-826F-4C97-A879-F3BD1C6EC7ABQ42322249-3E1DADF9-F285-4BC8-B630-694096123877Q42929252-E83E0180-A0D5-45E3-8F1B-3069FD392734Q42935227-A5C433FE-D3CB-4235-B9D0-6AF2C36C3F64
P2860
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
ATR inhibition broadly sensiti ...... py independent of BRCA status.
@en
type
label
ATR inhibition broadly sensiti ...... py independent of BRCA status.
@en
prefLabel
ATR inhibition broadly sensiti ...... py independent of BRCA status.
@en
P2093
P2860
P1433
P1476
ATR inhibition broadly sensiti ...... apy independent of BRCA status
@en
P2093
Amelia M Huehls
Andrea E Wahner Hendrickson
Catherine J Huntoon
Karen S Flatten
Larry M Karnitz
Shari L Sutor
P2860
P304
P356
10.1158/0008-5472.CAN-13-0110
P407
P577
2013-04-02T00:00:00Z